Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

AC 7700

Known as: AVE8062, Combretastatin A4 Analogue AVE8062, AC7700 
 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (1)

Serine
analogs & derivatives

Narrower (1)

ombrabulin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors
Purpose: The vascular disrupting agent ombrabulin rapidly reduces tumor blood flow and causes necrosis in vivo. A phase I dose… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Highly Cited
2008
Highly Cited
2008
Early Quantitative Evaluation of a Tumor Vasculature Disruptive Agent AVE8062 Using Dynamic Contrast-Enhanced Ultrasonography
Objectives:To evaluate the early tumor vasculature disrupting effects of the AVE8062 molecule and the feasibility of dynamic… Expand
Highly Cited
2007
Highly Cited
2007
Antitumor and antivascular effects of AVE8062 in ovarian carcinoma.
The purpose of this study was to examine the therapeutic efficacy and underlying mechanisms of action of a vascular-disrupting… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Review
2004
Review
2004
Vascular Targeting Agents as Cancer Therapeutics
  • P. Thorpe
  • Clinical Cancer Research
  • 2004
    • Corpus ID: 1739027
Vascular targeting agents (VTAs) for the treatment of cancer are designed to cause a rapid and selective shutdown of the blood… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Highly Cited
2003
Highly Cited
2003
Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis
We previously reported that a novel combretastatin A-4 derivative, AC7700, has remarkable antitumour effects because of an… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
2003
2003
Combination effect of AC‐7700, a novel combretastatin A‐4 derivative, and cisplatin against murine and human tumors in vivo
The in vivo combination effect of AC‐7700, a novel combretastatin A‐4 derivative, and cisplatin (CDDP) was examined. The… Expand
2003
2003
Differential relationship between changes in tumour size and microcirculatory functions induced by therapy with an antivascular drug and with cytotoxic drugs. implications for the evaluation of…
A novel combretastatin A-4 derivative, AC7700, which is now in Phase I clinical trials under a new code, AVE8062, has shown… Expand
Highly Cited
2002
Highly Cited
2002
A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs
In a previous study, we used subcutaneous LY80 tumours (a subline of Yoshida sarcoma), Sato lung carcinoma, and… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
1999
Highly Cited
1999
Antitumor Effects due to Irreversible Stoppage of Tumor Tissue Blood Flow: Evaluation of a Novel Combretastatin A‐4 Derivative, AC7700
The relation between tumor tissue blood flow (tBF) reduction and antitumor effects was investigated. Changes in tBF of normal… Expand
  • figure 1
  • figure 2
  • figure 3
  • table I
  • figure 4
Highly Cited
1999
Highly Cited
1999
A Novel Combretastatin A‐4 Derivative, AC‐7700, Shows Marked Antitumor Activity against Advanced Solid Tumors and Orthotopically Transplanted Tumors
AC‐7700, a novel combretastatin A‐4 derivative, suppresses the growth of solid tumors by inhibiting tumor perfusion. We evaluated… Expand
  • figure 1
  • table I
  • figure 2
  • table II
  • figure 3
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE